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Tapias1, José A. Carrión2, Xavier Forns1, Manel Juan3, Sofı́a Pérez-del-Pulgar1, Marı́a-
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Abstract
Real-life data showed an increased incidence of bacterial infections in patients with
advanced liver disease receiving a protease inhibitor (PI)-containing antiviral regimen
against hepatitis C (HCV). However, the causes of this event are unknown. We hypothe-
sized that PIs might impair innate immune responses through the inhibition of proteases
participating in the anti-bacterial functions of neutrophils and monocytes. The aims of the
study were to assess phagocytic and oxidative burst capacity in neutrophils and mono-
cytes obtained from patients receiving a PI containing-antiviral regimen, and to determine
cytokine secretion after neutrophil stimulation with flagellin. Forty patients with chronic
HCV (80% with cirrhosis) were enrolled in the study, 28 received triple therapy (Group A)
with pegylated-interferon and ribavirin for 4 weeks followed by the addition of a PI (tela-
previr, boceprevir or simeprevir), and 12 patients received an interferon-free regimen
(Group B) with simeprevir and sofosbuvir. Phagocytosis and oxidative burst capacity
were analyzed by flow cytometry at baseline, week 4, and week 8 of therapy. In neutro-
phils from Group A patients, oxidative burst rate and oxidative enzymatic activity per cell
significantly decreased throughout the study period (p = 0.014 and p = 0.010, respec-
tively). Pairwise comparisons showed a decrease between baseline and week 4 and 8 of
therapy. No differences were observed after the introduction of the PI. The oxidative
enzymatic activity per cell in monocytes significantly decrease during the study period
(p = 0.042) due to a decrease from baseline to week 8 of therapy (p = 0.037) in patients
from Group A. None of these findings were observed in Group B patients. Cytokine secre-
tion did not significantly change during the study in both groups. In conclusion, our data
suggest that the use interferon (rather than the PI) has a deleterious effect on neutrophil
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Cañete N, Mariño Z, Lens S, et al. (2016) Neutrophil
and Monocyte Function in Patients with Chronic
Hepatitis C Undergoing Antiviral Therapy with
Regimens Containing Protease Inhibitors with and
without Interferon. PLoS ONE 11(11): e0166631.
doi:10.1371/journal.pone.0166631
Editor: Golo Ahlenstiel, University of Sydney,
AUSTRALIA
Received: June 14, 2016
Accepted:November 1, 2016
Published: November 18, 2016
Copyright: © 2016 Gambato et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: SPP has received a grant from Instituto
de Salud Carlos III, Ministerio de Economı́a y
Competitividad (PI13/00155), co-funded by Fondo
Europeo de Desarrollo Regional (FEDER), Unión
Europea, Una manera de hacer Europa. XF has
received a grant from L’ Agència de Gestió d’Ajuts
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and monocyte phagocytic and oxidative burst capacity in this cohort of patients with HCV-
related advanced liver fibrosis.
Introduction
The use of triple therapy (TT), which combines a first generation protease inhibitor (PI) with
pegylated interferon (PegIFN) and ribavirin (RBV), was a major breakthrough in the treat-
ment of hepatitis C due to a significant increase in the chances of achieving sustained virologi-
cal response (SVR) [1–5]. However, the use of triple therapy (TT) was associated with an
important increase in the number of treatment-related adverse events (including infections,
clinical decompensation and death) in cirrhotic patients, especially in those with signs of portal
hypertension (platelet count<100,000 mm3) or liver dysfunction (albumin levels< 35g/L) [6–
8]. Moreover, in a recently published study by our group [9], patients with cirrhosis who
received TT presented a significantly higher number of bacterial infections as compared to cir-
rhotic patients treated with PegIFN and RBV (25% vs. 9%; p = 0.001). We also found that the
use of TT changed the pattern of infections with an increase in the number of respiratory tract
infections (particularly with gram-positive cocci) in the group of patients treated with this
combination. The latter differs from the typical infections observed in cirrhotic patients,
which are spontaneous bacterial peritonitis or spontaneous bacteremia caused by gram-nega-
tive bacilli. More recently, data from the TARGET cohort evaluating the efficacy and safety of
an IFN-free regimen (sofosbuvir [SOF] and simeprevir [SMV]) in liver transplant recipients
with advanced hepatitis C recurrence evidenced a non-negligible rate of bacterial infections of
14.6% [10].
It is well known that patients with cirrhosis are at higher risk of developing bacterial infec-
tions. As described in detail previously [9], there are several mechanisms to explain the
increased risk of infections in these patients including liver dysfunction, bacterial transloca-
tion, shunting, dysbiosis, immune dysfunction, and polymorphisms in NOD2 or TLR2 [11].
However, the change in the pattern of infections observed in patients receiving antiviral ther-
apy with a PI, prompted us to study other mechanisms. A possible explanation and the basis of
our hypothesis was that PIs might compromise the functions of different components of the
innate immune system. The efficiency of bacterial elimination depends on the rapid recruit-
ment of neutrophils from the circulation into the site of infection, phagocytosis and destruc-
tion of the microbe [12]. Similarly, monocytes/macrophages are essential in the initial host
reaction to infection by initiating an inflammatory response. The activation of monocytes/
macrophages is triggered by self and non-self recognition through specialized proteins
expressed in cell membrane including MHC (major histocompatibility complex) and TLR
(toll-like receptors) [13]. This recognition activates an intracellular cascade that leads to the
production of cytokines and chemokines.
Protease inhibitors against hepatitis C might impair the function of the innate immune sys-
tem by different mechanisms, such as blocking proteases/enzymes contained in neutrophils
and monocytes (which are crucial to microbe destruction). Indeed, an in vitro study using vari-
ous anti-HIV PIs showed a significant decrease in neutrophil functions including phagocyto-
sis, superoxide production and chemotaxis, and neutrophil apoptosis [14]. A recently
published study observed a decrease in neutrophils’ phagocytic capacity in patients receiving a
PI-containing antiviral regimen as compared to patients treated with dual therapy with
PegIFN and RBV [15]. Therefore, the aim of this study was to evaluate innate immune system
Neutrophil/Monocyte Function and Protease Inhibitors
PLOSONE | DOI:10.1371/journal.pone.0166631 November 18, 2016 2 / 14
Competing Interests:MCL has received advisory
fees from Janssen, BMS and Gilead. SL has
received advisory fees from Janssen, Gilead and
Abbvie. ZM has received advisory fees from BMS.
XF has received advisory fees from Gilead, Abbvie
and Janssen. The other authors have declared no
competing interest. This does not alter our
adherence to PLOS ONE policies on sharing data
and materials.
responses to infections assessing phagocytosis, oxidative burst capacity and cytokine produc-
tion in neutrophils and monocytes from patients with chronic hepatitis C undergoing antiviral
therapy with a PI-containing regimen with and without IFN.
Patients and Methods
Patients
Between February 2014 and March 2015, 40, genotype 1-infected patients with chronic hepati-
tis C who completed at least 8 weeks of antiviral therapy with a first generation PI (with or
without PegIFN and RBV) were included in this study. Patients were sequentially enrolled and
received an IFN-based TT (Group A) or an IFN-free therapy (Group B), as explained below.
Fibrosis stage was determined by transient elastography (F2: 7.6–9.4 kPa, F3: 9.5–14 kPa and
F4:14 kPa). In patients with fibrosis stage F4, an upper endoscopy and a hepatic venous gra-
dient pressure (HVPG) measurement were performed before treatment in order to determine
the presence of portal hypertension. Demographic, clinical and virological characteristics of
patients enrolled in Group A (n = 28) or Group B (n = 12), are depicted in Table 1. A control
group of 10 healthy individuals was also analyzed.
The study was approved by the Ethical Committee of the Hospital Clı́nic Barcelona and all
the participants provided written informed consent.
Antiviral therapy
First wave, first generation, PIs (TVR and BOC) were administered with PegIFN and RBV as
triple therapy (TT) until August 2014, when SMV, a second wave first generation PI became
available. The antiviral treatment with TT was indicated in patients with HCV-related chronic
liver disease (fibrosis stage2) or compensated cirrhosis. The contraindications to TT in cir-
rhotic patients were: the presence of clinically significant portal hypertension as determined by
an HVPG10 mmHg, the clinical evidence of portal hypertension (ascites, varices), a platelet
count<90,000 mm3, and a reduced synthetic liver function (assessed by bilirubin levels>2
mg/dL or albumin levels<35 g/L). Starting from November 2014, IFN-free regimens were
available and patients with cirrhosis were prioritized to receive IFN-free therapy with SOF plus
SMV with or without RBV for 12 or 24 weeks. None of the patients were on antibiotic
prophylaxis.
The first group of patients enrolled in the study (Group A) received TT with PegIFN α2a
(180 μg/week) and RBV (1000 or 1200 mg/d according to body weight) plus either TVR
(n = 10; 1125 mg bid), BOC (n = 2; 800 mg tid), or SMV (n = 16; 150 mg qd). In order to dis-
sect the potential effect of the PI during antiviral therapy, all patients received a 4 week lead-in
period of antiviral therapy with PegIFN and RBV before the addition of the PI. The duration
of TT was decided according to the specific package insert recommendations. The second
group of patients (n = 12; Group B) received an IFN-free regimen with SOF 400 mg daily plus
SMV 150 mg daily, with or without RBV (1000 mg or 1200 mg daily according to body weight)
for 12 or 24 weeks.
Monitoring and blood samples
All patients had outpatient clinic visits at baseline (day of treatment start), every 4 weeks dur-
ing therapy, and at weeks 4, 12 and 24 after the end of treatment. Clinical, and virological data
as well as any adverse event of special interest or that required a prescription medication for
management (cutaneous rash, anemia [hemoglobin<10 g/dL], infections) throughout treat-
ment and up to 24 weeks after the end of treatment, were recorded. HCV-RNA was measured
Neutrophil/Monocyte Function and Protease Inhibitors
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Table 1. Demographic, clinical and virological characteristics of the patients included in the study.
Characteristics(n = 40) IFN-based triple therapy (PegIFN/RBV+TVR/BOC/SMV) (n = 28) IFN-free therapy (SOF/SMV+RBV) (n = 12) p value
Age (years) 59 (37–71) 57 (43–77) 0.998
Liver disease stage; n (%) 0.591
• F0-1 0 1 (8%)
• F2-3 7 (25%) 0
• F4 21 (75% 11 (92%)
Previous IFN-based treatment; n (%) 16 (76%) 5 (42%) 0.290
Response to previous treatment; n (%) 0.227
• Non-Responder 11 (56%) 4 (80%)
• Relapser 7 (44%) 1 (20%)
IL28B Polymorphism; n (%) 0.679
• CC 5 (18%) 2 (17%)
• CT 13 (46%) 7 (58%)
• TT 3 (11%) 2 (17%)
• Unknown 7 (25% 1 (8%)
Protease inhibitor; n (%) NA
• Telaprevir 10 (36% -
• Boceprevir 2 (7%) -
• Simeprevir 16 (57%) 12 (100%)
Neutrophils (x 103 cells/mm3) 2.9 (1.5–5.3) 2.6 (1.2–4.2) 0.688
Monocytes (x 103 cells/mm3) 0.4 (0.2–0.8) 0.4 (0.2–0.9) 0.745
Platelets (x 103 cells x mm3) 137 (68–204) 92 (34–393) 0.016
• >100.000 4 (17%) 8 (67%) 0.006
Total bilirubin (mg/dL)) 0.8 (0.4–1.8) 0.9 (0.3–2.1) 0.344
AST (IU/mL) 77 (36–194) 89 (51–170) 0.420
ALT (IU/mL) 115 (45–221) 79 (43–155) 0.184
Albumin (g/L) 44 (38–50) 43 (34–47) 0.294
• < 35 g/L 0 1 (8%) 0.343
INR 1.1 (0.9–1.2) 1.2 (1–1.3) 0.016
MELD score 8 (6–12) 8 (6–12) 0.123
Child-Pugh score 5 (5–6) 5 (5–6) 0.440
Viral load (IU/ml x 106)
• Baseline 1.8 (0.0011–24 2.9 (0.013–3) 0.363
• Week 4 (lead in in TT) 0.002 (0–3.8) 0 (0–0.0008) 0.000
• Week 8 0 (0–0.013 0 0.851
Response to treatment; n (%) 0.066
• SVR12 18 (64% 11 (92%)
• Relapse 3 (11%) 1 (8%)
• Breakthrough 4 (14%)
• Stopping rule 1 (4%)
• Stop due to adverse events 2 (7%)
Side effects; n (%) 0.000
• Anemia 8 (35%) 0 0.021
• Neutropenia 2 (9%) 0 0.425
• Thrombocytopenia 4 (17%) 0 0.169
• Infections 3 (13%) 0 0.271
Continuous data are expressed as median (range). PegIFN: Pegylated interferon, RBV: Ribavirin, TVR: Telaprevir, BOC: Boceprevir, SMV: Simeprevir,
SOF: Sofosbuvir. AST: Aspartate-amino transferase, ALT: Alanin-amino transferase, INR: International Normalized Ratio, MELD: Model for End-Stage
Liver disease, TT: Triple Therapy
doi:10.1371/journal.pone.0166631.t001
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by quantitative polymerase chain reaction with a limit of quantification of 15 IU/mL (VER-
SANT HCV RNA 1.0 Assay, Siemmens). Sustained virological response (SVR) defined as
HCV-RNA<15 IU/mL that persisted 12 weeks after the end of antiviral treatment.
Blood samples (15 mL) from patients who underwent TT were prospectively obtained at
baseline, week 4 (at the end of lead-in phase), week 8 (4 weeks after PI initiation), and week 12
of therapy (in 8 patients receiving TT with SMV). Blood samples from patients who received
IFN-free treatment, were prospectively collected at baseline and week 4 of treatment.
Phagocytic and oxidative burst activities of neutrophils and monocytes
In order to determine the phagocytosis of neutrophils and monocytes, Phagotest1 kit was
used. The kit contains fluorescein-labeled opsonized E. coli bacteria and other reagents, as
reported in the manufacturer’s description. Briefly, heparinized whole blood, processed within
2 h of sampling, was incubated with the FITC-labeled E. coli bacteria at 37˚C and a negative
control sample remained on ice. The phagocytosis was stopped by placing the samples on ice
and adding quenching solution. This solution allowed the discrimination between attachment
and internalization of bacteria by quenching the FITC fluorescence of surface bound bacteria
leaving the fluorescence of internalized particles unaltered. After two washing steps with wash-
ing solution erythrocytes were then removed by addition of lysing solution. Data were ana-
lyzed by flow cytometry (BD FACS Canto™) evaluating 2 parameters as recommended in the
kit: 1) the proportion of cells undergoing phagocytosis in general (phagocytosis rate, P-R),
expressed as percentage and indicating the ingestion of one or more bacteria per cell, and 2)
the individual phagocytic activity per cell (the number of bacteria engulfed per cell), corre-
sponding to the median fluorescence intensity (P-MFI). The number of cells recorded per
experiment ranged between 15.000 and 20.000. An example of the gating strategy is shown in
S1 Fig.
In order to measure the oxidative burst activity of neutrophils and monocytes, Phagoburst
kit1 was employed. The kit contains unlabeled opsonized E. coli bacteria as particulate stimu-
lus, the protein kinase C ligand Phorbol 12-Myristate 13-Acetate (PMA) as high stimulus, the
chemotactic peptide N-formyl-MetLeuPhe (fMLP) as low physiological stimulus, dihydrorho-
damine (DHR)-123 as a fluorogenic substrate and other reagents as reported in the manufac-
turer’s description. Briefly, heparinized whole blood, processed within 2 h of sampling, was
incubated with the various stimuli at 37˚C, a sample without stimulus served as negative con-
trol. Upon stimulation with unlabeled E.coli, neutrophils and monocytes produced reactive
oxygen metabolites (superoxide anion, hydrogen peroxide, hypochlorous acid) which
destroyed bacteria inside the phagosome. Formation of the reactive oxidants during the oxida-
tive burst has been monitored by the addition and oxidation of DHR-123. The reaction was
stopped by addition of lysing solution, which removed erythrocytes and allowed a partial fixa-
tion of cells. Data were analyzed by flow cytometry (BD FACS Canto™) measuring 2 parame-
ters: 1) the proportion of cells having produced reactive oxygen radicals (burst rate, B-R),
expressed as percentage, and 2) the burst enzymatic activity per cell, corresponding to the
median fluorescence intensity (B-MFI). The number of cells recorded per experiment ranged
between 15.000 and 20.000.
In vitro studies of phagocytic and oxidative burst activities of neutrophils
and monocytes
To evaluate the isolated effect of IFN and PIs on phagocytic and oxidative burst capacity of
neutrophils and monocytes, heparinized whole blood from four cirrhotic patients and four
healthy controls was incubated at 37˚C during 3h with or without (negative control): SMV
Neutrophil/Monocyte Function and Protease Inhibitors
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(5μM and 0.05μM, OLYSIO1 Janssen); TVR (5μM and 0.05μM, INCIVO1 Janssen) and IFN-
αA/D (50U/mL and 5000U/mL, Sigma-Aldrich). Drug stock solutions were prepared in
DMSO and working dilutions were done in DMEM. Phagotest1 and Phagoburst1 were per-
formed as reported above. Each experiment was performed in duplicate.
Measurement of cytokine secretion by neutrophils
Cells isolation. Neutrophils were isolated from the whole blood into a band free from red
blood cells, using Polymorphprep™ solution. Briefly, a layer 5.0 ml of anticoagulated whole
blood were layered over 5.0 ml of Polymorphprep™ in a 15 ml centrifuge tube and centrifuged
at 1000 x g for 45 minutes in a swing-out rotor at 18–22˚C. After centrifugation, two leucocyte
bands were visible: the top band of peripheral blood mononuclear cells and the lower band of
neutrophils, while the erythrocytes were pelleted. The neutrophil band was harvested using a
Pasteur pipette and diluted by addition of culture medium in a 15 ml tube. The cells were spun
down twice (at 18–22˚C, 400 x g, 10 min) and then re-suspended in medium.
Toll-like receptor-5 stimulation. After cell isolation and count to obtain 106 cells/mL,
100 μL of the cells were added to 96-well culture plates and were stimulated with 1 μL of flagel-
lin (concentration 100μg/mL, FLA), a monomeric constituent of bacterial flagella, that is a
TLR-5 agonist. The cells, with and without FLA, were incubated at 37˚C for 8 hours.
Cytokine determination. The supernatant of neutrophils was collected separately and
cryopreserved to -80˚ for further analysis. Quantification of specific cytokines secretion (IL-
1b, IL-6, IL-10, IL-12) was performed using Luminex1. The supernatant of unstimulated neu-
trophils was used as control for Luminex1 determinations.
Statistical analysis
Continuous variables are depicted using median and ranges (or mean with standard devia-
tion), and categorical variables are expressed as absolute numbers and percentages. Mann-
Whitney non-parametric test was used to compare data from healthy controls and baseline
data from the patients included in the study. A one-way repeated measures ANOVA was used
to determine whether there was a statistical difference in P-R, P-MFI, B-R, B-MFI, IL-1b, IL-6,
IL-10, and IL-12 over the course of the 3 time points during antiviral therapy (baseline, W4,
W8) in patients treated with IFN (Group A). Post hoc tests with Bonferroni adjustments were
used to examine the pairwise combinations. When the assumption of normality was violated, a
logarithmic transformation of the variable was performed. If despite the transformation, the
variable continues having a no-normal distribution comparisons between groups were per-
formed using the Friedman test (P-R and B-R in neutrophils, and P-MFI and B-MFI in mono-
cytes). Again pairwise comparisons were performed with a Bonferroni correction for multiple
comparisons. The Wilcoxon test was used to analyze the difference between the 2 time points
in Group B patients. All differences were considered significant at p-value of<0.05. Statistical
analyses were performed with SPSS, version 20 (SPSS, Chicago, IL).
Results
Effectiveness and tolerability of antiviral therapy
Sixty-four percent and 92% of the patients included in Groups A and B, respectively, achieved
SVR. During antiviral treatment, anemia (n = 8), neutropenia (n = 2), thrombocytopenia
(n = 4), and 3 episodes of bacterial infections of minor clinical relevance (urinary [n = 1], gas-
trointestinal [n = 1] and skin [n = 1]) with no positive cultures were observed only in Group A
patients. No hematological or clinical adverse events were observed in Group B patients.
Neutrophil/Monocyte Function and Protease Inhibitors
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Phagocytic activity of neutrophils and monocytes
At baseline, patients in Group A (n = 28) had significantly lower rates of neutrophils undergo-
ing phagocytosis (P-R) as compared to healthy controls (n = 10) (p = 0.006). However, there
were no differences in the number of bacteria engulfed per cell (P-MFI) between patients and
healthy controls at baseline. Neutrophil P-R and P-MFI did not change throughout the study
period in both groups of patients (S2A–S2D Fig). Likewise, monocyte P-R was similar between
controls and patients and it did not change in the specific time-points in both groups (S2E and
S2F Fig). In contrast, monocyte P-MFI was significantly higher at baseline as compared to con-
trols in Group B patients (p = 0.043, S2H Fig). No changes were observed during the study
period in both groups of patients (S2E–S2H Fig). Raw data and p values for pairwise compari-
sons are shown in S1 and S2 Tables. In patients from Group A, there were no significant
changes in both parameters according the type of PI administered (data not shown).
Oxidative burst activity of neutrophils and monocytes
At baseline, there were no significant differences between patients and healthy controls in both
groups (Fig 1A–1D). In Group A, neutrophil burst rate (B-R) significantly decreased through-
out the study period (p = 0.014) (Fig 1A). Pairwise comparisons evidenced a decrease between
baseline and week 4 of therapy at the limit of significance (p = 0.063) and a statistically signifi-
cant decrease between baseline and week 8 of therapy (p = 0.023). No differences were
observed between week 4 and 8 of therapy indicating no effect of the PI introduction. Simi-
larly, oxidative enzymatic activity per cell (B-MFI) significantly decreased during the study
period (p = 0.010) with a decrease at week 4 and 8 of therapy as compared to baseline
Fig 1. Oxidative burst capacity of neutrophils. Panel A and B show the burst rate (B-R) in patients treated
with triple therapy and IFN-free regimen, respectively. Panel C and D show the enzymatic activity per cell
(median fluorescence intensity, B-MFI) in patients treated with triple therapy and IFN-free regimen,
respectively. Data are analyzed at baseline (before starting antiviral therapy), and at week 4 and 8 of therapy.
* These comparisons were performed by Friedman tests.
doi:10.1371/journal.pone.0166631.g001
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(p = 0.056 and p = 0.018, respectively) (Fig 1C). There were no significant differences after the
introduction of the PI (p = 1.000). In the 8 patients with blood sample at week 12 of therapy
(TT with SMV), there was also a significant decline of B-MFI as compared to baseline
(p = 0.028) but not different from the results at week 4 or 8 of therapy (data not shown).
Monocyte B-R did not change in Group A patients (Fig 2A), while monocyte B-MFI decreased
during the study period (p = 0.042) (Fig 2C). Pairwise comparisons revealed a significant
decrease at week 8 of therapy as compared to baseline (p = 0.037). On the other hand, in
Group B patients, neutrophil and monocyte B-R and B-MFI did not change throughout the
study period (Figs 1B, 1D, 2B and 2D). Raw data and p values for pairwise comparisons are
shown in S1 and S2 Tables.
In vitro experiments
As shown in S3A–S3D Fig P-R, B-R and B-MFI in neutrophils were similar in blood from cir-
rhotic patients and healthy controls. However, P-MFI was lower in cirrhotic patients as com-
pared to healthy controls. In both groups of patients, there were no differences in P-R, B-R,
P-MFI and B-MFI of neutrophils after incubation of human blood with 2 different concentra-
tions of interferon, TVR and SMV as compared to blood incubated with DMEM. In mono-
cytes, there were no differences in P-R, B-R, P-MFI and B-MFI between cirrhotic patients and
healthy controls (S4A–S4D Fig). The percentage of monocytes engulfing bacteria (P-R)
decreased with the addition of 50U and 5000U of IFN as compared to that of monocytes from
blood incubated only with DMEM (33% vs. 54% and 44% vs. 54%, respectively) (S4A Fig). In
addition, there was a decrement in the percentage of monocytes producing reactive oxygen
radicals (B-R) with the addition of IFN as compared to that of monocytes from blood
Fig 2. Oxidative burst capacity of monocytes. Panel A and B show the burst rate (B-R) in patients treated
with triple therapy and IFN-free regimen, respectively. Panel C and D show the enzymatic activity per cell
(median fluorescence intensity, B-MFI) in patients treated with triple therapy and IFN-free regimen,
respectively. Data are analyzed at baseline (before starting antiviral therapy, n = 28), and at week 4 and 8 of
therapy. * These comparisons were performed by Friedman tests.
doi:10.1371/journal.pone.0166631.g002
Neutrophil/Monocyte Function and Protease Inhibitors
PLOSONE | DOI:10.1371/journal.pone.0166631 November 18, 2016 8 / 14
incubated only with DMEM (30% vs. 51% and 42% vs. 51%, respectively) (S4C Fig). None of
these changes were observed with the addition of different concentrations of a PI (TVR or
SMV). Regarding P-MFI and B-MFI in monocytes, there were no significant changes after the
addition of IFN or a PI (S4B and S4D Fig).
Cytokine secretion
Regarding innate immune recognition, we assessed the secretion of IL-10, IL-12, IL-1b, IL-6,
TNFα by neutrophils before and after stimulation with FLA. The secretion of IL-10 and IL-12
remained at the lower limit of detection even after stimulation; therefore they were not consid-
ered in the final analysis. In both groups, neutrophils stimulation with FLA did not induce a
significant change in IL-6, TNFα and IL-1b secretion throughout the study time-points (nei-
ther after 4 weeks of lead-in with PegIFN and RBV nor after the introduction of the PI) (data
not shown).
Discussion
Real-life data have strongly suggested that an increased number of bacterial infections occurs
in patients with cirrhosis receiving triple antiviral therapy with TVR or BOC, especially those
with low platelets and low albumin levels [7–9]. Indeed, in a previous study we found that TT
was the only independent predictor of bacterial infections in a group of cirrhotic patients
receiving this antiviral regimen (25% vs. 9% in patients treated with dual therapy with PegIFN
and RBV; p = 0.001). Interestingly, there was also a change in the pattern of infections with an
increase in the number of respiratory tract infections (12% vs. 1%; p = 0.049) which is different
from the infections commonly observed in patients with cirrhosis (whether or not receiving
antiviral therapy with an IFN-based regimen) [9, 16, 17].
In this prospective study we hypothesized that neutrophil and monocyte dysfunction
induced by a deleterious effect of anti-HCV PIs, could partly explain the increase in bacterial
infections observed in patients treated with a PI-containing regimen. Our hypothesis was sup-
ported by the fact that anti-HIV PIs have been shown to impair neutrophil functions including
phagocytosis, superoxide production and chemotaxis, and neutrophil apoptosis in vitro [14].
Moreover, a recently published study evaluated the neutrophil function in patients receiving
triple antiviral therapy in comparison to patients with chronic hepatitis C treated with dual
therapy with PegIFN and RBV [15]. As previously described, the authors observed a signifi-
cantly higher number of infections in patients receiving TT (31%) as compared to patients
receiving dual therapy (26%; p = 0.045). Interestingly, and from a pathogenic point of view,
the authors also demonstrated a 40% decrease in neutrophil phagocytic capacity at the end of
therapy in PI-treated patients that was not evidenced in patients treated with dual therapy.
Phagocytic capacity recovered 24 weeks after treatment discontinuation. Oxidative burst was
also lower in patients treated with TT (especially in those receiving TVR) as compared to the
control group of patients on dual therapy.
Our results did not confirm the data by Spindelboeck et al as we did not find a significant
decrease in neutrophil or monocyte phagocytic capacity during TT with TVR, BOC or SMV.
Conversely, we observed a decrease in the proportion of cells producing reactive oxygen radi-
cals (B-R) and in neutrophil oxidative enzymatic activity per cell (B-MFI) after 4 weeks of
lead-in therapy with PegIFN and RBV as compared to baseline in Group A patients (treated
with TT). This effect was more pronounced at week 8 but did not change significantly between
weeks 4 and 8 of therapy (suggesting no effect of the addition of a PI). In monocytes, there was
also a decrease in the enzymatic activity per cell (B-MFI) at week 8 of therapy as compared to
baseline with no changes between week 4 and 8 (addition of the PI). None of these changes
Neutrophil/Monocyte Function and Protease Inhibitors
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were observed in Group B patients (treated with an IFN-free regimen containing a PI). In vitro
experiments conducted to confirm the clinical results, showed a decrease in P-R and B-R in
monocytes (but not in neutrophils) with the addition of IFN and no changes with the addition
of different concentrations of PIs.
Thus, our results suggest a predominant effect of IFN, rather than the PI, on neutrophils’
and monocytes’ function. IFN-based therapy has been clearly associated with an increased risk
of infections, especially in patients with decompensated cirrhosis [16]. As described in detail
previously, the explanation for this phenomenon is unknown [18–20]. Some studies including
patients with chronic hepatitis C (with and without cirrhosis) have observed an increase in
neutrophil oxidative burst and phagocytic capacity during therapy as compared to baseline
values [21–23]. Giorgini et al, suggested that the enhancement in neutrophil and monocyte
function during antiviral therapy with an IFN-based therapy could be explained by a compen-
satory effect to the IFN-induced bone marrow toxicity. In this sense, IFN therapy would select
a more resistant population of neutrophils and monocytes with improved chemotactic and
oxidative burst capacity [21]. Similarly, Jablonowska et al [22] and Piazzola et al [23] found an
increase in the production of reactive oxygen species by neutrophils in patients treated with
IFN. Moreover, several studies have observed monocyte activation, either in vitro after stimu-
lation with IFN [24] or through the determination of biomarkers of monocyte activation (solu-
ble CD14 or IL-18 levels) [25]. However, we found opposite results with a decline in the
oxidative burst capacity of neutrophils and monocytes after IFN therapy. One explanation
would be that in patients with cirrhosis, phagocytic cells are not able to activate such compen-
satory mechanisms. Cirrhotic patients present a state of immune paralysis secondary to the
chronic stimulation of immune cells by microbial and damage-associated molecular patterns
(MAMPs or DAMPs) leading to innate and adaptive immune cell exhaustion [11].
The in vitro experiments provided two major results: 1) The phagocytic activity per cell
(P-MFI) was lower in blood from cirrhotic patients as compared to healthy controls. This
result was not unexpected due to the well known impairment of phagocytosis observed in
patients with advanced liver disease [11], and 2) There was a significant decline in B-R and
P-R in monocytes (but not in neutrophils) after the incubation of blood from cirrhotic patients
with 2 different concentrations of IFN that were not observed after the addition of a PI, which
confirm the in vivo results. Surprisingly, these changes were not observed in neutrophils. The
explanation for this phenomenon is unknown, but it is possible that in the experiment condi-
tions, neutrophils were less sensitive to IFN as compared to monocytes. This has also been
reported in a previous study in which the intensity of STAT1 fluorescence was lower in neutro-
phils and lymphocytes as compared to monocytes after stimulation with IFNγ and IFNα [26].
The differences in our results with the study by Spindelboeck et al [15] could also be
explained by the differences in the design of both studies: 1) In contrast to theirs, our current
study included predominantly patients with cirrhosis which could have some degree of base-
line immune dysfunction, 2) Our study design was different, since we did not compare a
cohort with TT vs. a cohort of patients receiving dual therapy with PegIFN and RBV, but all
patients in our study population received a 4 week lead-in period of PegIFN and RBVmaking
each patient its own control (this might avoid the potential inter-individual variations in
immune responses), and 3) The current study has a limited number of data at week 12 of ther-
apy in Group A patients (n = 8) which hampers the evaluation of a more prolonged use of PIs
on immune function. On the other hand, the current results do not confirm the data from the
real-life cohorts pointing PI-containing regimens as a risk factor for the development of bacte-
rial infections. The possible explanation for these results is that despite our current study
enrolled predominately patients with cirrhosis, the degree of liver dysfunction or portal hyper-
tension in these patients is much lower than in those analyzed in previous cohorts [7, 9].
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Indeed, only 1 and 12 patients the current study had albumin levels<35g/L and platelet counts
<100,000, respectively. This would point towards an important role of liver disease severity in
the pathogenesis of infections when using a PI-containing antiviral regimen. Moreover, this
might also explain the relative low magnitude of the changes in neutrophil and monocyte oxi-
dative enzymatic activity observed during antiviral therapy in the current study. It is possible
that the analysis of neutrophil and monocyte function in patients with more advanced liver
disease would have shown a more pronounced impairment in phagocytosis or oxidative burst
capacity during antiviral therapy. Unfortunately, this is difficult to demonstrate because the
use IFN is contraindicated in patients with liver dysfunction.
The main limitations of our manuscript are: 1) IFN-based therapies in combination with a
PI are not longer administered in most of the countries worldwide, 2) The small sample size of
the current cohort that was related to the rapid changes in the antiviral regimen prescribed
during the study period, 3) The small number of patients with bacterial infections observed
during the course of therapy in patients included in this study which hampers the comparisons
of phagocytic and oxidative burst capacity between patients with and without infections, and
4) We did not analyze other mechanisms involved in the immune pathogenesis of bacterial
infections such as chemotaxis or migration of immune cells to the site of infection, or a poten-
tial deleterious effect of PI on other cells such as NK, γδ T cells or dendritic cells. Thus, we can-
not completely rule-out the negative effect of PI in the immune system.
Despite these results, assessing the potential causes of an increased number of infections in
patients receiving a PI is still relevant for several reasons. First, infections have also been
reported in patients receiving a PI as part of an IFN-free regimen (SMV plus SOF) [10]. Sec-
ondly, PIs still are an important component of current and future IFN-free regimens (i.e. SMV
in combination with SOF, Paritaprevir/r in combination with Ombitasvir with or without
Dasabuvir, Grazoprevir plus Elbasvir, etc).
In conclusion, our data suggest that the use IFN (rather than the PI) has a deleterious effect
on neutrophil and monocyte phagocytic and oxidative burst capacity in patients with hepatitis
C-related advanced liver fibrosis receiving antiviral therapy.
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S2 Fig. Phagocytic capacity of neutrophils (Panels A-D) and monocytes (Panels E-H).
Panel A, B, E and F show the rate of phagocytic capacity (P-R) in patients treated with triple
therapy and IFN-free regimen. Panel C, D, G and H show the number of bacteria engulfed by
cell (median fluorescence intensity, P-MFI) in patients treated with triple therapy and IFN-
free regimen. Data are analyzed at baseline (before starting antiviral therapy), and at week 4
(treatment only with PegIFN and RBV) and 8 (TT) of therapy.  These comparisons were per-
formed by Friedman tests.
(PPTX)
S3 Fig. In vitro data of phagocytic and oxidative burst capacity in neutrophils with differ-
ent concentrations of interferon, simeprevir and telaprevir. Panel A shows the rate of
phagocytic capacity (P-R). Panel B shows the number of bacteria engulfed by cell (median
fluorescence intensity, P-MFI). Panel C shows the burst rate (B-R). Panel D shows the enzy-
matic activity per cell (median fluorescence intensity, B-MFI). Black bars expressed the results
in blood from cirrhotic patients and grey bars expressed the results in blood from healthy con-
trols. Data are expressed as mean and standard deviation. IFN50: Interferon 50 U/mL,
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activity per cell (median fluorescence intensity, B-MFI). Black bars expressed the results in
blood from cirrhotic patients and grey bars expressed the results in blood from healthy con-
trols. Data are expressed as mean and standard deviation. IFN50: Interferon 50 U/mL,
IFN5000: Interferon 5000 U/mL, SMV0.05: Simeprevir 0.05 μM, SMV5: Simeprevir 5 μM,
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